Details

Autor(en) / Beteiligte

• Chierchia, Gian-Battista
• Di Giovanni, Giacomo
• Ciconte, Giuseppe
• de Asmundis, Carlo
• Conte, Giulio
• Sieira-Moret, Juan
• Rodriguez-Mañero, Moises
• Casado, Ruben
• Baltogiannis, Giannis
• Namdar, Mehdi
• Saitoh, Yukio
• Paparella, Gaetano
• Mugnai, Giacomo
• Brugada, Pedro

Titel

Second-generation cryoballoon ablation for paroxysmal atrial fibrillation: 1-year follow-up

Ist Teil von

• Europace (London, England), 2014-05, Vol.16 (5), p.639-644

Ort / Verlag

England: Oxford University Press

Erscheinungsjahr

2014

Link zum Volltext

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Background The novel cryoballoon Advance (CB-A) has proven to achieve significantly lower temperatures and faster pulmonary vein isolation (PVI) times in comparison with the first-generation device. Although acutely very effective, to the best of our knowledge, data on mid-term clinical follow-up is lacking. Aims The aim of the study was to analyse the freedom from recurrence of atrial fibrillation (AF) on a 1-year follow-up period, in a series of consecutive patients having undergone PVI with the CB-A for paroxysmal AF (PAF). Methods and results Forty-two patients [30 male (71%); mean age: 57.9 ± 21.1 years] were included. All patients underwent a procedure with the large 28 mm CB-A. A total 168 PVs were depicted on the pre-procedural computed tomography scan. All PVs (100%) could be isolated with the CB only. The freedom from AF off-antiarrhythmic drug treatment after a single procedure was 78% of patients at a mean 11.6 ± 2.0 months follow-up. If considering a blanking period (BP) of 3 months, success rate was 83%. Phrenic nerve palsy (PNP) was the most frequent complication occurring in 19% of individuals. Conclusion The CB-A is very effective in producing PVI and affords freedom from AF at 12 months follow-up in 83% of patients affected by drug-resistant PAF following a 3-month BP. The most frequent complication observed was PNP which occurred in 19% of patients. All PNP reverted during follow-up.